|
TTC4 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.01110000039206E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.1056999999991E-05 |
| Normal-vs-Stage2 |
1.969220E-04 |
| Normal-vs-Stage3 |
4.61480000002457E-06 |
| Normal-vs-Stage4 |
2.1781999981485E-08 |
| Stage1-vs-Stage2 |
4.545800E-01 |
| Stage1-vs-Stage3 |
5.316600E-01 |
| Stage1-vs-Stage4 |
4.072400E-02 |
| Stage2-vs-Stage3 |
8.101200E-01 |
| Stage2-vs-Stage4 |
3.372400E-01 |
| Stage3-vs-Stage4 |
1.356360E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.2702000002095E-07 |
| Normal-vs-AfricanAmerican |
1.979520E-02 |
| Normal-vs-Asian |
4.619500E-04 |
| Caucasian-vs-AfricanAmerican |
4.134000E-01 |
| Caucasian-vs-Asian |
5.388800E-01 |
| AfricanAmerican-vs-Asian |
7.251600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.79099999778154E-08 |
| Normal-vs-Female |
9.23859999946153E-07 |
| Male-vs-Female |
7.084300E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.63069999999222E-05 |
| Normal-vs-Age(41-60Yrs) |
5.26420000035444E-07 |
| Normal-vs-Age(61-80Yrs) |
6.81930000023812E-07 |
| Normal-vs-Age(81-100Yrs) |
1.497840E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.044000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.870650E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.678600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.548400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.912600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.310400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.884000E-02 |
| Classical-VS-Follicular |
2.252300E-02 |
| Classical-VS-Other |
3.046600E-01 |
| Classical-VS-Normal |
2.004100E-04 |
| Tall-VS-Follicular |
8.191400E-01 |
| Tall-VS-Other |
9.817600E-01 |
| Tall-VS-Normal |
3.85820000000647E-05 |
| Follicular-VS-Other |
9.355400E-01 |
| Follicular-VS-Normal |
2.16419999999884E-05 |
| Other-VS-Normal |
2.431900E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.94759999969396E-07 |
| Normal-vs-N1 |
2.59769999955139E-08 |
| N0-vs-N1 |
7.019600E-02 |
|
|
